“The level of responsibility for young people in the Israeli army trains them for entrepreneurship and they see startups as a way to follow the Jewish idea of Tikun Olam — improving the world,” said Cukierman
Rome (askanews) – Building a technological bridge between small and medium-sized Italian companies and the innovative companies of Israel, which is called the “start up Nation” for the quantity and quality of its researchers, its research centers and its businesses Technology: this is the goal of GreenMedSummit, an event that aims to meet Italian and
“Over the past five years we have been committed to investing in core investment banking and private equity,” said Edouard Cukierman, Chairman and Founder of the Cukierman Investment Group in Israel. “We will continue to work hard to promote cross-border cooperation.”
Eloxx Pharmaceuticals, focused on the discovery, development and commercialization of compounds for the treatment of genetic diseases such as cystic fibrosis and cystinosis, received $24 million from the Israeli-Chinese Catalyst CEL Fund, Pontifax and other industry players. In May, Eloxx entered into a merger agreement with Sevion Therapeutics.
Fan, managing partner of the Israeli-Chinese Catalyst CEL Fund and head of the merger and acquisition department at China Everbright Ltd., is in Israel this week as the fund announces its latest investment in the Israeli company Eloxx Pharmaceuticals.
קרן CEL Catalyst מודיעה על השקעתה בחברת אלוקס פארמצבטיקה Pharmaceuticals Eloxx ,המפתחת תרופות למחלות גנטיות הנגרמות על ידי ‘מוטציות פסק’ (mutations sense-non .(קרן CEL Catalyst הישראלית סינית היא בין המשקיעים המרכזיים בסיבוב גיוס בהיקף 24 מליון דולר, יחד עם קרן ההון סיכון הישראלית Pontifax המתמחה במדעי החיים ושחקנים מובילים אחרים בתעשייה.
Eloxx Pharmaceuticals Ltd, a clinical stage company developing drugs for genetic diseases, raised $24 million in an investment round led by Catalyst CEL Fund and Israeli life sciences venture capital fund Pontifax, among others, Catalyst said on Wednesday.
TEL AVIV — Eloxx Pharmaceuticals Ltd, a clinical stage company developing drugs for genetic diseases, raised $24 million in an investment round led by Catalyst CEL Fund and Israeli life sciences venture capital fund Pontifax, among others, Catalyst said on Wednesday.